Manzanita Trees In Northern Arizona

BLOG OPHTHALMOLOGY CEUTA EYES: PRECAUTIONS IN CATARACT SURGERY IN PATIENTS WITH TREATMENT EYE OPHTHALMOLOGY


www.qxeyes.com

The use of tamsulosin within 14 days of cataract surgery has been associated with serious postoperative problems, according to an article published in the Journal of the American Medical Association . X

tamsulosin in alpha-adrenergic blocker that has been commonly prescribed to treat benign prostatic hyperplasia, and which has been described that increases the risk of intraoperative complications during cataract surgery. But until recently were not described the potential postoperative complications after use of tamsulosin versus other alpha-blockers used in the treatment of prostate disease. X

The paper has compared the complications between patients treated with tamsulosin versus other alpha-blockers, and the existence of recent exposure to tamsulosin (14 days prior) or from 15 to 365 days earlier, on a set of 3550 patients treated with tamsulosin and 7426 treaties with other alpha-blockers. X

adverse effects have been reported in 284 patients (0.3%), including 100 cases of suspected endophthalmitis, 175 cases of detention crystal fragments, 35 detachments and 26 cases of retinal detachment and retention of fragments. These effects were not observed with the use of other alpha-blockers. X

The study concludes that "exposure to tamsulosin in the 14 days prior to cataract surgery has been shown related to increased incidence of serious postoperative complications eye, whereas no association was found with other alpha-blockers used to treat benign prostatic hypertrophy.
X
Since the combination of cataract surgery and treatment with tamsulosin is relatively common for patients should be warned of potential risks, and the ophthalmologist must plan and schedule the surgery as compared to potential intraoperative complications (floppy iris syndrome) and postoperative. To this end, different strategies have been proposed as strong cycloplegic dilation (atropine or homatropine), high density viscoelastic agents, low flow intraoperative use of iris retractors or other stabilization procedures or pupillary dilation.
X
JAMA. 2009; 301:1991-1996, 2044-2045. X

Basic information and guidance. To personalized information consult your ophthalmologist.
x
CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira

Tv Center Pro Windows 7

TAMSULOSIN CEUTA: NEW PERSPECTIVES GENE THERAPY IN THE EYES OF OPHTHALMOLOGY

A recent study by researchers at the University of Washigto n has been estaurar color vision in adult monkeys with impaired perception of red and green.
x
The study was published in the journal "Nature" ("Colour blindness corrected by gene therapy"), and its makers claim that the treatment could work in humans, says Jay Neitz, leader of the team.
x
The study represents a significant advance, since until now the scientific community does not think it was adult brain can be manipulated to correct color blindness. Thus, it is considered only during the first years of life, when there is greater "plasticity" cerebral, it was possible to add new sensory information to people, which may improve vision.
x
Neitz teacher team managed to introduce therapeutic genes into cells in the retina of the eye of an adult male monkey, containing the DNA code needed for cells could distinguish between red and green.
x
therapy seems to have been a success, since the treated monkeys were able to pass tests of color, being able to correctly identify the red forms that appeared in green funds.
x
Animals received treatment for two years, scientists have managed to keep its vision corrected from those tests.
x
Still to assess what might be the long-term effects of treatment.
x
As explained by Dr Winfried Amoaku, an expert in ophthalmology at the University of Nottingham UK (United Kingdom), speaking to the BBCA, said the research could benefit approximately 7% of men and 1% de las Mujeres born with vision problems.
x
basic information and guidance. For a personalized information see su ophthalmologist.
x

OJOS of Ceuta. Innovating in Ophthalmology.
Ophthalmological Center DR. Medina Catoira

Ojos de Ceuta - Innovating in Ophthalmology Ophthalmological Center Dr. Medi Catoira

Denise Milani akiba-online

DALTON CEUTA: PRECAUTIONS IN CATARACT SURGERY IN PATIENTS with tamsulosin

www.qxeyes.com

A retrospective study published in the Journal of the American Medical Association shows the association between the use of tamsulosin , a drug commonly used in the treatment of benign prostatic hypertrophy , and the presence of serious complications during and extraoperatorias during cataract surgery.
X
The study shows that patients who receive or have received recent treatment with tamsulosin in the 14 days prior to surgery have a significantly higher incidence of complications in surgery cataract, increased incidence that it has been observed with other alpha-blockers used in the treatment of benign prostatic hypertrophy (BPH) .
X
Tamsulosin is a drug blocking alpha-adrenergic receptor that is frequently prescribed for the treatment of prostatic hypertrophy. Given its frequent use, patients should be warned of the perioperative risks and the ophthalmologist must be prepared for possible complications, since the suspension of treatment before surgery so does not reduce the risk of complications such as intraoperative floppy iris syndrome (IFIS).
x
To reduce potential intraoperative complications (IFIS, capsular rupture, vitreous loss, retinal detachment, ..) have proposed pharmacologic strategies and instruments such as the use of cycloplegic powerful (atropine, homatropine), denser viscoelastic under fluid flow, iris retractors, pupil dilator rings and expanders.
x
Both the patient and the ophthalmologist should be aware, be advisable for the surgeon to warn the patient before surgery if you are undergoing treatment with Tamsulosin for prostatic hypertrophy (Omnic, Omnic Geese, Urolosin, Urolosin geese) .
x
JAMA. 2009; 301:1991-1996, 2044-2045.

x
Basic Information and indicative. For personalized information consult your ophthalmologist.
x
CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN
Eyes

Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira

Gay Saunas In Gloucester

CEUTA OPHTHALMOLOGY EYE: THE VITAMIN B6, B12 and Folic Acid CAN REDUCE THE RISK OF MACULAR DEGENERATION ASSOCIATED WITH AGE IN WOMEN

A study published in the journal Archives of Internal Medicine seems to show that the daily diet supplemented with Folic Acid, Pyridoxine and Cyanocobalamin seems reduce the risk of macular degeneration associated with age in women with cardiovascular disease risk.

Epidemiological studies indicate an association between elevated levels homocysteine \u200b\u200b blood and the risk of wet AMD , so researchers Brigham and Women's Hospital, Harvard Medical School in Boston, Massachusetts, and colleagues from the Women's Antioxidant and Folic Acid Cardiovascular Study have examined results of the incidence of wet AMD in women with elevated homocysteine \u200b\u200blevels which has been treated combined with folic acid, pyridoxine (B6) and cyanocobalamin (B12) , compared with placebo. The average duration of follow up was 7.3 years.

finally The results showed a lower incidence of wet AMD in the treated group, statistically significant, reducing the risk of it.

Since there are currently no meansof prevent AMD in the initial stages, except the strict smoking ban, these results become important clinically and should be confirmed in other populations of men and women.

Arch Intern Med. 2009, 169:335-341.

Basic information and guidance. For personalized information consult your ophthalmologist.

CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira

Laser Anniversary Joke

CEUTA OPHTHALMOLOGY EYE TREATMENT WITH LOW DOSES OF retinal vein occlusion fibrinolytic

retinapanama.com

A recent study in Retina (July / August 2009 - vol 29 - 932-940 ps) seems to indicate the improvement in outcome in patients with retinal vein occlusion treated with low doses of fibrinolytics compared to those treated with hemodilution.
x
The RESEARCHERS s ( Hattenbach, Lars-Olof MD; FRIEDRICH ARNDT, CARL MD; Lerche, RALF MD; Scharrer, INGE MD; Baatz, Holger MD, margin, FABRICE MD; Richard, Gisbert MD; BEHRENS- BAUMANN, WOLFGANG MD; OHRLOFF, CHRISTIAN MD ) Ometer s randomly 53 patients with occlusion of the central retinal vein (CRVO) or occlusion of branch retinal vein (BRVO ) to treatment with intravenous thrombolysis with 50 mg of recombinant tissue plasminogen activator (rt-PA) or hemodilution within the 11 days of onset of symptoms.
x
All patients were followed up one year.
x
Among patients with CRVO half BCVA was 20/60 in the rt-PA group compared to a BCVA of 20/400 in the hemodilution group.
x
Among patients with BRVO, there was a trend toward improved vision in rt-PA group differences did not reach statistical significance, probably due to the small number of patients group.
x
Basic information and guidance. For personalized information consult your ophthalmologist.
x

CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira

Wedding Ribbon With Sayings

CEUTA OPHTHALMOLOGY EYE: Drops OPHTHALMIC NERVE GROWTH FACTOR IN THE TREATMENT OF GLAUCOMA OPHTHALMOLOGY

www.visionparaiso.com

A team of Italian researchers reported in the August 4 edition of Proceedings of the National Academy of Science (Act of the National Academy of Sciences), evidence shows that eye drops containing nerve growth factor improved the vision in three patients with advanced glaucoma
X
The team of researchers Alessandro Lambiase, Luigi Aloe, Marco Centofanti, Vincenzo Pariso, Flavio Mantelli, Gilberto Bucci, Stefano Bonini, Rita Levi-Montalcini and evaluated Colofrancesco Valeria effects of eye drops based on "Nerve Growth Factor" in a rat glaucoma model and subsequently developed a clinical study of three patients with progressive visual field defects despite control eye pressure.
x
Glaucoma was induced in rats by injection of hypertonic saline episcleral vein. Initially evaluated at 100 and 200 mg / mL on the results in 24 rats, determinándosa most effective dose of 200 mg / mL. A second group underwent histological, biochemical and molecular methods on a group treated for 7 weeks, bringing the best indices in relation to the control group. It was aimed at a slower loss of nerve fibers and cell death by apoptosis in the treated group versus the control group.
x
The clinical study on three patients with advanced glaucoma treated psycho and electrofuncionales parameters analyzed after three months of treatment with topical "Nerve Growth Factor."
x
treated patients showed a long-term improvement of visual field, optic nerve function, contrast sensitivity and visual acuity.
x
Studies seem to show that the factor exerts neuroprotective effects Creimiento Nervous, inhibiting apoptosis in animals with glaucoma. In the 3 patients with advanced glaucoma with topical treatment "Nerve Growth Factor" improved all parameters of visual function.
x
These results may open new therapeutic perspectives in the treatment of glaucoma and other neurodegenerative diseases of the optic nerve.
x
Integrato di Ricerca Center, Department of Ophthalmology, University of Rome "Campus Bio-Medico" and Fondazione Alberto Sordi, 00128 Rome, Italy - Institute of Neurobiology and Molecular Medicine, National Research Council, 00143 Rome, Italy - Department of Ophthalmology, University of Rome "Tor Vergata", 00133 Rome, Italy - Gian Battista Bietti Eye Foundation, Rome, Italy - European Brain Research Institute Foundation, 00143 Rome, Italy.
x
Basic information and guidance. For personalized information consult your ophthalmologist.
x
CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira

I Have Had A Stroke Card

CEUTA EYES: Encapsulated Cell Technology (ECT) FOR DRY MACULAR DEGENERATION EYE OPHTHALMOLOGY

* *

* *
*







http://www.neurotechusa.com/ect/about_encapsulated_cell_technology.asp

Encapsulated Cell Technology (ECT), developed by the company Neurotech (Rhode Island) has managed to keep the vision in the vast majority of patients who participated in Phase II clinical trial conducted for the treatment of degeneration Macular Seca.
*
So far there is no effective treatment for dry AMD, a leading cause of blindness in people over 55 in developed countries.
*
The 96.3% of patients receiving high dose treatment have maintained stable vision after a follow up of 12 months, although it is the patients with better acuity initial visual (2 / 3 or more) that have benefited most.
*
Patients with stable vision have also developed a thickening of their retinas, which seems aumeto translate a density of photoreceptors. * ECT
The implant is a small device (about the size of a grain of rice) contains cells capable of providing consistently and continuously called ciliary neurotrophic factor protein involved in stabilizing macular.
*
Preclinical studies have been funded by the Foundation Fighting Blindness, like esudios maintains phase II / III for treatment of retinitis pigmentosa, Usher syndrome and coroidemia.
*
The results of these trials will be announced at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) meeting in the month of May in Fort Lauderdale (Florida).
*
View previous post:

http://ojosdeceuta.blogspot.com/2007/01/estado-del-tratamiento-de-la.html
*
Basic Information and Guidance. For a custom Info consult your ophthalmologist.
*

CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira

Appraisal Districts In Scottsdale In Arizona

CEUTA: STEM CELL TRANSPLANT FOR AMD. EYE OPHTHALMOLOGY

+ +

+

+ +

We get questions about the story recently published in many media on Degeneration Treatment MACULAR STEM CELLS.

*

British scientists from University College London (UCL) have developed a treatment study (clinical trial) for Macular Degeneration (AMD) - from the use of stem cells, which could begin to implement by 2015.

*
The study of treatment is to replace the layer of eye cells that have undergone a degenerative process because of the age by new cells derived from embryonic stem cell manipulation.

*

This is a new phase of clinical trial initiated in 2007 (v http://www.fundacion-vision.org.py/docs_v2020/tema227.pdf er). According to Professor Peter Coffey, UCL Institute of Ophthalmology, the tests performed so far in the laboratory have yielded a satisfactory result.

*

The procedure is to generate in the laboratory of RPE cells qa replacement from stem cells. These new cells are then injected into the affected area (macular region).

*

already before the scientists themselves have made cell autotransplantation in patients with good prospects, but it is a complicated intervention they manage a few cells (autologous), which limits its use.

*

aim is to establish a protocol that intervention can be reduced to a 45-minute procedure under local anesthesia.

* Scientists from UCL and Moorfields Hospital, working now to produce cells that can be used clinically with the announced financial support of Pfizer, await first test starting in 2011, once receive authorization medical authorities in the UK.

* Once established steps and protocols is expected that intervention can be reduced to a 45-minute procedure under local anesthesia.

*

Being a trial still in development, is not expected its application to clinical practice until 2015.

*

Basic information and guidance. For personalized information consult your ophthalmologist.

*

CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
Eye Center DR. CATOIRA MEDIN

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira

Best Facial Moisturizers In The United States

CEUTA: DSAEK, NEW ALTERNATIVE IN CORNEA TRANSPLANT



http://www.craigbergermd.com/images/ DSAEK_before_after.jpg

70 percent of patients with severe corneal damage can benefit from a new technology for corneal transplantation with endothelial cells. DSAEK technique improves vision, accelerated postoperative recovery and resistance remains against corneal trauma.

*

Service Ophthalmology Hospital Reina Sofía de Murcia , apply a new technique for corneal transplantation with endothelial cells (DSAEK) indicated for 70 percent of patients with severe corneal damage (at 30 percent is required conventional entire cornea transplant).

*

The benefits of the new technique are derived from the procedure itself, since it is not necessary to transplant the entire cornea to replace the damaged endothelial cells by the sound of a dead donor. The results are overwhelming compared to the classical intervention in patients who have injured only a thin layer of cells located in the back of the cornea, which occurs in seven out of ten injuries requiring transplantation. To recover you replace only 10 microns of tissue, compared with 550 microns of thickness of the cornea.

*
Drs Gutierrez and Amanda Ramon Ortiz , Ophthalmology Service, Hospital General Universitario Reina Sofía apply this type of transplant regularly since 2007 and have conducted more than 38 interventions, of which 29 have been carried out in the hospital Murcia.

*

The technical DSAEK notable improvements over traditional transplants (which will be used in other corneal injuries) recovered an average view of 85 percent, compared with 45 percent of conventional transplant; postoperative period of three months versus two years off work for three weeks instead of eight months, the astigmatism generated by the replacement of cells is 0.06 to 4.5 diopters versus traditional transplant and, in addition, the cornea is resistant to trauma.

*

Another advantage is that it requires eighteen twenty-four stitches completely essential in transplantation, namely by a four-millimeter incision to remove damaged cells and restore the sound.

*

The cornea remains intact, does not lose its transparency, and recovery tantola patient's vision is obtained in a few weeks, whereas with traditional transplants require two years to gain a mediocre final and the eye is weakened against bumps and knocks.

*

Likewise, natural preserve all the nerves of the cornea, avoiding the negative repercussions of their disappearance in full transplantation (dryness, loss of corneal sensitivity ...). The surgical procedure is also simplified as it is not necessary to open the eye.

*

The transplanted healthy endothelial tissue adheres to the natural bed by an air bubble and the patient, after an hour of rest, you can go home. After a week will be enough to get around. The overall vision is recovering from two to three months after the intervention, while the whole transplant thing to do after refractive surgery to achieve an acceptable view, apart from the complications of the sutures involved return to the operating room more than once.
*
The technical DSAEK has been developing since 1999 when the first operations were performed by Dr. Gerrit Melles, the Institute for Innovative Ocular Surgery in Rotterdam, Holland. Some NHS facilities have been isolated interventions, but most English casuistry is the tandem González-Ortiz public hospital in Murcia, with 38 cases, followed by a private clinic in Cordova has 20. In the rest of the world's main series is the American Mark Ferry, at the Institute Devers, Portman (Oregon) with 500 organ transplants, mientras que la Rotterdam has 100 cases.

*

basic information and guidance. To see a personalized intervention su ophthalmologist.

*

OJOS of Ceuta. Innovating in Ophthalmology.

Ophthalmological Center DR. Medina Catoira

Ojos de Ceuta - Innovating in Ophthalmology Ophthalmological Center Dr. Medi Catoira

Spinal Stenosis And Horseback Riding

CEUTA OPHTHALMOLOGY EYE: CONTACT LENSES FOR PREVENTION OF BLINDNESS EYE OPHTHALMOLOGY


* * *

* *


* * *


* * *

Complutense University of Madrid presented at the Salon of Inventions in Geneva an invention on such an important issue the prevention of blindness.
-
When we cataract surgery, as we age, our natural defenses against the visible light wear, or simply disappear. To avoid this, the Group of Neuro-Computing and Neuro-Robotics, led by Dr. Celia Sánchez Ramos, has developed a filter system that applied to lenses, intraocular both contact and contribute to the prevention and treatment of retinal damage caused by natural and artificial light. protecting the retina during adulthood, and may even prevent blindness.
-
The product is to add a protection for contact lenses to eliminate the negative effects of exposure to natural and artificial light.
-
is a normal lens, which can be graduated or not, which was applied a yellow pigmentation. Replaces the natural protective eye, we all lose with time and especially with cataract surgery. _

The invention of the University of Madrid is to compensate and prevent the degeneration of the retina. The solution is safe, economic, invisible and easy. You can apply to any type and design of contact lens with or without graduation. _

Researchers have worked for 5 years in animal studies and human clinical trials. First, we studied mice exposed to different types of light, their retinas were analyzed and shown which was part of the natural and artificial light that causes damage in the retina. In the next round of contact lenses were made UCM-AET to the animals for producing a barrier to harmful light. Experiments showed that our lenses block these bands get negative in the right proportion, acting invisible, no hassle, and above all, demonstrating that produce the protective effect. _

The team Complutense de Madrid also has conducted experiments with rabbits, which have been operated for cataract to simulate how light affects humans with these conditions. It was found that the genes that protect the retina are increased in animals artificially protected, while those that cause cell death, and therefore, blindness, are increased in animals that have no protection. Experimental studies have been presented at conferences on the best view of the entire world. _

With this treatment the lenses remain totally invisible and perception of colors and contrasts is not altered. These results were confirmed by extensive clinical trials in people over the last four years. _

The researchers are convinced that soon, all contact lenses and intraocular lenses in the world will protect the eyes against retinal damage induced by natural and artificial light. _

Although still not sold, several U.S. companies have been interested in marketing.
http://www.plataformasinc.es/index.php/Noticias/Lentillas-contra-la-ceguera-prevenible-en-el-Salon-de-Inventos-de-Ginebra
* *

Basics and indicative. For personalized information consult your ophthalmologist.
*

CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. CATOIRA MEDIN

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira

How To Look Cute When Iceskating

CEUTA: COMMENTS ON VISUAL HEALTH SPANISH EYES CEUTA

image: http://zdzlhospital.com

IV According to the results of health study English visual, conducted by Transitions Optical in 2009 on the prevention and maintenance of the visual health of English, 20% of respondents say they have never gone to the ophthalmologist for an eye examination.

So only 30% of respondents have gone to the specialist to perform a review once a year (we recommend an annual review), and 26% believe it is only necessary to go to an ophthalmologist if one has or is believed to have an eye problem.

However, 95% of respondents consider the view as the most important sense. And 77% has placed the vision in first place when assessing what is feared losing physical abilities during the course of life, followed by physical mobility (65%), memory (48%), hearing (9 %) and libido (3%).

With respect to the use of some form of vision correction, 71% of English ago Goggles or contacts or both at once. English for those over 55 years, this percentage is 93% and those between 18 and 34 drops to 54%. Retirees (93%) and homemakers (83%) are the most used collective vision correction systems.

regard to activities or situations can affect the visual health, the English believe that reading in dim light is what most affects your eyes (91%), followed by watching TV too close (88%) and expose eyes to UV radiation (83%).

In the latter, despite the fact that UV rays are present during the 365 days a year, 84% of respondents consider the summer as the season where your eyes can suffer from overexposure to UV rays, followed far behind by the winter (9%) , Spring (6%) and autumn (1%).

The Visual Health Study that Transitons Optical performed in Spain since 2005, also carried out since 2006 in countries that form the EMEA region: France, Germany, United Kingdom, Portugal, Netherlands, Italy and South Africa. Spain has taken a sample through 2000 surveys of population over 18 years.

This is the fourth consecutive year to perform this study, one of whose main objectives is to educate the English population of the importance of taking care of their eyes, 365 days a year, because you only have two and are for life. "

source: Transitions Optical.

Basic information and guidance. For personalized information consult your ophthalmologist.

CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
EYE CENTER DR. MEDIN CATOIRA

Eyes

Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira

Toshiba Live.jpg Login

OPHTHALMOLOGY: A STUDY RELATED EXCESS INTAKE OF RED MEAT WITH THE INCIDENCE OF DEGENERATION OF AGE-RELATED MACULAR OPHTHALMOLOGY

* *


* * *


* * *

macular degeneration associated with age is a major cause of loss of central vision and blindness among older people. Not sufficiently known etiology, including its causes have been postulated, among others, diet and ultraviolet radiation.

*

A recently published study by researchers at the Centre for Eye Research Australia, University of Melbourne, seems to link the excess consumption of red meat with a higher incidence of this disease.

*

The authors conducted a study on a group of 6734 people aged 58-69 years between the years 1990-94 through records fundus fundus, meat consumption was analyzed by frequency of intake of meats as responses to a questionnaire-based food. In Seguiment the set (years 2000-2006) to determine the presence of 1680 cases of AMD (macular degeneration associated with age) start and 77 cases of advanced AMD.

*

The results show the association of the high consumption of red meat with the onset of AMD, regardless of whether the consumer was fresh or processed meat. No relationship was found between AMD and increased consumption of chicken meat.

*

abuse So red meat, consuming ten times a week red meat is associated with an increase around 47 percent, macular degeneration, "according to the report's author, Dr. Elaine Chong. Likewise, the researcher noted that people who ate sausages and salami suffered by the condition that who ate chicken.

*

These results suggest that the consumption of different types of meat differently affect AMD risk and the need for further studies and changes in dietary habits and lifestyle. The macula is the center of the retina and controls the vision to read, watch television and recognize faces.

*
http://aje.oxfordjournals.org/cgi/content/abstract/169/7/867
*

Basics and guidance. For personalized information see your ophthalmologist.

*

CEUTA EYES. INNOVATION IN OPHTHALMOLOGY .
EYE CENTER DR. CATOIRA MEDIN

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira

Scott Kay Engagement Artiste

CEUTA EYES: EYE FOR ELECTRONIC amblyopia treatment


source: www.ophthocare.com

* *

* *

* * *


* * *



* *

Until very recently the only existing treatment for amblyopia was the use of the patches and the appropriate optical correction, if needed.
*
OphthoCare Israeli company recently presented a novel treatment that does not require the use of patches, it has developed the first liquid crystal glasses, which work with an electronic shutter.
*
This goggle has been approved by the U.S. FDA for treatment of amblyopia in children, and is expected to revolutionize the treatment of this anomaly, which affects 5% of children, whose treatment is recommended to between 3 and 6 years.

* consists of a liquid crystal glasses that darken by patch, the electronic shutter is incorporated into the optical correction and is controlled by a preprogrammed microchip which is activated on the eye to small intervals. These sessions "close-open" exercise the lazy eye and force its use.

* Through the liquid crystal technology, generate an electronic curtain closing the shutter over the good eye and, therefore, requires the use of the weak eye. The closing takes place automatically and can last approximately 10 to 15 seconds, then opened for 10 or 15 seconds. The exercises of "open-close" will continue while the patient uses glasses, lazy eye strengthening and improving visual acuity and binocular vision exercising.
*
Although it has great advantages, the children reported that they felt very comfortable using the glasses, thus becoming a preferred alternative in terms of patches.

* Being a technology implementation, the major drawback for now is cost.
*
Basic information and guidance. For personalized information consult your ophthalmologist.

* *
CEUTA EYES. INNOVATION IN OPHTHALMOLOGY .
Eye Center DR. CATOIRA MEDIN

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira

Pobierz John Deere Am Builder Deluxe

CEUTA OPHTHALMOLOGY EYE OF DEVELOPMENT EYE. MY LIFE PROTECTS EYES CEUTA

Several people have asked us information on eye development in conjunction with the campaign "PROTEGE MIVIDA" against abortion.

*

Although we have our personal opinion, given the medical nature of our blog, try to remain neutral, so that everyone must draw their conclusions.

*

Development EYE:

• 4 weeks (6-mm embryo. And 0.5 ozs.) Vesicles are already visible that will result in the eye.
• 5 weeks (embryo of 14 mm. Approx.): The eyes begin to take shape.
• 2 months (4-cm fetus. And 5 ozs.): The eyes are beginning to stand out, though not more than a few small holes in the skull. Can already be observed the formation of the eyelids, over the lens of the eyes, over the next few days, taken as ovalada.Los upper and lower eyelids are joined and closed, not open until the seventh month.
• 5 months (fetus of 25 cm. And 250 grams approx.) Appear eyebrows and eyelashes, starting to be covered with an incipient or hair lanugo.
• month 7 (fetus of 35 cm. And 1,200 ozs.) Opens and closes his eyes and the eyeballs are perfectly formed and ready to perform its functions. Perceives light as a faint reddish glow.
• 9 th month (45/50 cm fetus. And 2.500/3.200 ozs.): The training process is complete anatomical and visual device is fully developed, with the exception of the most important of the retina, which finishes its development late in the first year of the child.

In the newborn is characteristic of the Iris color, usually blue-gray to reach its final color after a few months.

Basic information and guidance. For personalized information consult your ophthalmologist.

CEUTA EYES. INNOVATION IN OPHTHALMOLOGY .
Eye Center DR. CATOIRA MEDIN

extended information can be found in www.discapnet.es

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira

What Is't The Lotto Number

OPHTHALMOLOGY: SPANISH ASSOCIATION OF ANIRIDIA


image: http://www.glaucomaconsultantsnorthwest.com/NewFiles/glauc-aniridia.jpg
*

* * *


* * *


* *
*

send us your address and new website the SPANISH ASSOCIATION OF ANIRIDIA.

* The affected or concerned about this disease can be contacted at:
*
c / Valladolid 12, office 3
28922 Alcorcon (Madrid)
Phone / Fax: 916439799
*
e-mail: web asoaniridia@telefónica.net
: www.aniridia.es

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira

What's The Hardest Hitting Bowling Ball?

melatonin might be a safe treatment for blepharitis and uveitis

Recent published studies by Sande et al in the American Journal of Pathology "seem to suggest that treatment melatonin may be useful in the treatment of uveitis.

Patients affected by this process often have red, swollen eye and visual impairment.

untreated, uveitis can lead to permanent vision loss. Thus, in U.S. Encompasses the 10-15% of the causes of blindness.

Its causes can be manifold, ranging from autoimmunity, ocular trauma, cancer, infection, rheumatoid arthritis, multiple sclerosis ...

In many cases there is no fully effective treatment, and treatment with corticosteroids may lead to side effects such as glaucoma and cataracts.

The study findings show that melatonin, which regulates the sleep cycle can prevent ocular inflammation secondary to uveitis. It has been found that two factors that contribute to inflammation TNFa and NFKB, are reduced by treatment with melatonin. Tratamieno also reduces the accompanying clinical symptoms such as capillary dilation, eye redness, and cataracts, while helping to maintain the blood-ocular barrier.

Alone or in combination with corticosteroids, anti-inflammatory effects of melatonin can benefit patients with chronic uveitis and reducing the rate of complications secondary to treatment with corticosteroids, but are to establish the exact mechanisms by which melatonin help to reduce eye inflammation, which should be subject of further studies.

http://www.eurekalert.org/pub_releases/2008-11/ajop-mms111708.php

Basic information and guidance. For personalized information consult your ophthalmologist.

CEUTA EYES. INNOVATION IN OPHTHALMOLOGY Eye Center DR. CATOIRA MEDIN

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira

Descargar Pokemon Shiny Silver

Image: http://www.bellezones.com/

blepharitis (inflammation of the eyelid margin) in many cases may be related to the use of cosmetic products that sometimes cause a reaction in the skin scaly eyelids, styes, meibomian cyst or small inflammation of the sebaceous glands of the eyelid.

*

Thus, allergic blepharitis may occur from contact with cosmetic products are applied to eyelids, such as pencils, shadows, blushes, creams ... and by the proper use of solvents used to remove products.

*

Although these products can not only be its origin, but any cosmetic substance or from another source: nickel, lacquer, plastics, acrylics, hand cream and even some plants can cause dermatitis acute or Chronicles of the eyelids and blepharitis.

*

Although blepharitis is not contagious, we need a thorough cleaning and continuous eyelid hygiene. Treatment may involve ointments ophthalmic antibiotics or steroids.

*

should wash hands thoroughly and gently brush the affected areas and scale with a damp gauze or a cotton swab dipped in eye drops and ointment. Do not clean the leaves or "scratch" with the fingers, as it increases the risk of infection.

*

The process must be repeated 2 or 3 times a day for a week, still needs to be repeated periodically as preventative maintenance.

* is also recommended not to share pens and products cosmetics due to possible spread of germs normal skin and in case of pencils, sharpen them before use to remove the first layer.

*

Basic information and guidance. For personalized information, consult your ophthalmologist.

*

CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.

EYE CENTER DR. CATOIRA MEDIN

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira

Primer Melting Temperature Calculation Fa

MAKEUP Statin therapy may cause damage of the eye muscles



Source image: http://fundacionspes.org

Statins are a group of drugs commonly used to reduce cholesterol, protect against any damage that may result from heart disease and prevent heart attacks .

* Statins work by reducing plasma cholesterol and lipoproteins in the liver by inhibiting HMG-CoA reductase and increasing the cell surface the number of hepatic receptors for LDL. This will prevent the entry excessive amounts of cholesterol in the bloodstream.
*
now form a group of drugs prescribed on a common basis, and include lovastatin (Mevacor, Aterkey, Colesvir, Mevasterol, Nergadan, Taucor), simvastatin (Zocor, Alcosin, Arudel, Belmalip, Colemin, Glutasey, histopathologic, Inegy, Lipociden, Pantok) provastatina (Pravachol), fluvastatin (Lescol, Digaril, Lymetel, Vaditon, Liposit) and atorvastatin (Lipitor, Cardile, Prevencor, Zarator).
* em
Posted 01/07 / The results of a recent study published in the journal Ophthalmology in December ( Ophthalmology . 2008, 115 (12) :2282-2285) suggest that some disorders of ocular motility and muscle such as diplopia, ptosis and ophthalmoplegia may be associated with statin therapy at normal doses.
*
Dr. FW Fraunfelder and Dr. Amanda B. Richards Casey Eye Institute, Oregon Health & Science University in Portland (USA) investigated the effects of this kind in their hospital care to several patients with diplopia and ptosis associated with statin therapy.
*
then collected cases in the National Registry of Drug-Induced Ocular Side Effects , WHO and the FDA. and identified in the database 256 patients (143 men, 91 women and 22 without gender specified) with diplopia, ptosis or ophthalmoplegia associated with statins.
*
The average patient age was 69 years. The dose varied among the different statins, although the average dose was within the limits recommended in the SPC of each drug. The median time to onset of the adverse effect of the drug was 8 months.
*
Of the 256 patients in 62 interrrumpido disorders disappeared with statin treatment. In Sixteen patients diplopia or ptosis reappeared on restart statin therapy. This suggests a provocative test is positive and convincing evidence of this adverse effect of statins.
*
Although this adverse effect is uncommon, probably represents a localized myositis in the extraocular muscles because statins can cause myositis in other skeletal muscles of the body, doctors who prescribed drugs in this class (statins) should know this possible adverse effects of the drug and assess the treatment interruption appears diploplia, ptosis or ophthalmoplegia.

http://www.osnsupersite.com/view.aspx?rid=33934

http://www.eurekalert.org/pub_releases/2008-12/aaoo-od0112508. php

Basic information and guidance. For personalized information, see your ophthalmologist .

CEUTA EYES. INNOVATION IN OPHTHALMOLOGY.
Eye Center DR. CATOIRA MEDIN

Eyes Ceuta - Innovating Ophthalmology Ophthalmology Center Dr. Medín Catoira